# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Puma Biotechnology (NASDAQ:PBYI) affirms FY2025 sales outlook from $212.000 million-$222.000 million to $212.000 million-$222.0...
Puma Biotechnology (NASDAQ:PBYI) sees Q3 sales of $48.000 million-$51.000 million vs $60.000 million analyst estimate.
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.15 per share which beat the analyst consensus estimate of $0...
Puma Biotechnology (NASDAQ:PBYI) reported quarterly earnings of $0.10 per share which beat the analyst consensus estimate of $(...